TLR7 and congenital rubella syndrome: However, there is no evidence to suggest that therapy with a TLR7 agonist for more extended periods and/or at higher doses may have greater impact on T2 inflammation, and previous data indicate that participants treated with doses of GSK2245035 greater than 20 ng report more CRS-related adverse events [13,27].